Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.

YS Huang, CY Cheng, BH Liou, PL Lu, SH Cheng, YT Lee, CE Liu, HY Sun, CJ Yang, HJ Tang, SP Lin, MW Ho, SH Huang, HC Tsai, Chih-Hung Lee, CC Hung

研究成果: 期刊稿件文章同行評審

10 引文 斯高帕斯(Scopus)

摘要

The efficacy and safety of switching from tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has not been widely investigated in HIV/HBV-coinfected Asian population. Between February and October 2018, HIV/HBV-coinfected patients who had achieved HIV viral suppression with TDF-containing regimens were switched to E/C/F/TAF. Assessments of plasma HBV and HIV viral load, HBV serology, renal function, lipid profiles, and bone mineral density (BMD) were performed at weeks 24 and 48 after switch. A total of 274 HIV/HBV-coinfected participants were enrolled, with 12.8% testing HBeAg-positive and 94.2% having plasma HBV DNA <20 IU/mL at baseline. At weeks 24 and 48, 92.7% and 89.8% achieved plasma HBV DNA <20 IU/mL; 4.7% and 5.1% had HBV DNA ≥20 IU/mL; and 2.6% and 5.1% had no data, respectively. At weeks 24 and 48, 95.6% and 94.2% of participants maintained HIV RNA <50 copies/mL, respectively. Compared with baseline, the median urine β2-microglobulin-to-creatinine ratio at week 48 decreased significantly from 241 to 134 μg/g (p<0.001). The mean BMD of the spine and hip improved at week 48 (+1.77% and +1.33%, respectively). Significantly higher lipid profiles were observed after switch to E/C/F/TAF. Thirteen (4.7%) patients withdrew from the study before week 48, with 7 (2.6%) due to adverse effects. Switch to E/C/F/TAF maintained HBV and HIV viral suppression and resulted in improvement of proteinuria and BMD of the spine and hip, but increased lipid levels in HIV/HBV-coinfected patients at week 48.
原文美式英語
期刊Journal of acquired immune deficiency syndromes (1999)
86
發行號4
DOIs
出版狀態已出版 - 2021

指紋

深入研究「Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.」主題。共同形成了獨特的指紋。

引用此